Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer

This is a first-in-human, open-label, Phase 1 study evaluating BBI-940, an investigational kinesin oral molecular degrader, administered as monotherapy or in combination with fulvestrant in adults with advanced or metastatic breast cancer.

Trial Details

NCT ID
NCT07408089
Phase
PHASE1
Sponsor
Boundless Bio, Inc.
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • BBI-940
  • Fulvestrant
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Lake Success, New York, United States|40.77066,-73.71763
  • Austin, Texas, United States|30.26715,-97.74306
  • Dallas, Texas, United States|32.78306,-96.80667
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Adults with locally advanced or metastatic breast cancer, including estrogen receptor-positive/human epidermal growth factor receptor 2-negative (E…
  • Prior treatment with standard therapies known to provide clinical benefit, appropriate for disease subtype and study part, including endocrine ther…
  • Measurable disease per RECIST v1.1, except for participants enrolled in Part 1A.
  • Molecular eligibility as applicable by study part, including absence of an ESR1 mutation (Part 2A) or presence of FGFR1 amplification (Part 2B), ba…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →